Study Summary
This trial is testing a new treatment for lymphoma that involves using mosunetuzumab alone for four cycles, followed by an assessment of response. If the patient responds well, they will continue treatment with mosunetuzumab. If the patient does not respond well, they will receive mosunetuzumab with lenalidomide augmentation during the next four cycles.
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Non-Hodgkin's Lymphoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Time of study registration through end of follow-up, approximately 5 years.
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
Planned Therapy
1 of 1
Experimental Treatment
52 Total Participants · 1 Treatment Group
Primary Treatment: Mosunetuzumab · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there currently any open enrolment opportunities for this research initiative?
"As per the information posted on clinicaltrials.gov, this trial is actively seeking patient participants. It was initially published on July 14th 2022 and has been recently amended as of November 17th 2022." - Anonymous Online Contributor
How many participants are actively engaged in this clinical experiment?
"Genentech, Inc. is seeking a total of 52 participants that meet the criteria for this trial and will be operating it out of two sites: Rutgers Cancer Institute in New Jersey and Yale Cancer Center in Connecticut." - Anonymous Online Contributor
Could you enlighten me on any other experiments involving Mosunetuzumab?
"Mosunetuzumab was first studied at Saint Joseph Regional Medical Center-Mishawaka in 2004; since then, 347 clinical trials have been concluded. Currently 277 are actively recruiting participants, many based out of New Brunswick, New Jersey." - Anonymous Online Contributor
To what extent might Mosunetuzumab be hazardous to patients?
"Mosunetuzumab's safety is rated at a 2, as the Phase 2 trial indicates this drug has some evidence of being safe but none demonstrating its efficacy." - Anonymous Online Contributor
What medical applications has Mosunetuzumab been utilized for?
"Mosunetuzumab is a frequently employed treatment for multiple myeloma and other refractory lymphomas, chronic lymphocytic leukemia, and conditions requiring two prior systemic chemotherapy regimens." - Anonymous Online Contributor